Company
Samsung Biologics Co.,Ltd.
Headquarters: Incheon, South Korea
Employees: 3,247
CEO: Mr. John Chongbo Rim
Market Cap
₩73.879 Trillion
KRW as of July 1, 2025
US$54.48 Billion
Samsung Biologics Co.,Ltd. Categories
South Korea Healthcare BiotechnologySouth Korea Healthcare South Korea Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $309.91 B |
| Vertex Pharmaceuticals Incorporated | $117.36 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $59.14 B |
| Marinomed Biotech AG | $58.56 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Detailed Description
Samsung Biologics Co., Ltd. engages in the contract manufacturing organization business for biopharmaceuticals products. It is involved in the provision of contract development organization services, including cell line development, upstream and downstream processes, and analytical methods and formulations. The company also offers aseptic filling, lyophilization, finishing, storage and shipping, and support services; and quality assurance and control, as well as biosafety and analytical testing services. In addition, it engages in the development and commercialization of biosimilar drugs; and manufactures mammalian cell-based antibody drugs. The company has a strategic partnership agreement with Kineta, Inc. Samsung Biologics Co., Ltd. was founded in 2011 and is headquartered in Incheon, South Korea.
Financials
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | ₩4.899 T |
| EBITDA | ₩2.399 T |
| Gross Profit TTM | ₩2.584 T |
| Profit Margin | 26.12% |
| Operating Margin | 37.49% |
| Quarterly Revenue Growth | 37.10% |
Stocks & Indices
Samsung Biologics Co.,Ltd. has the following listings and related stock indices.
Stock: KRX: 207940 wb_incandescent